Evidence map›Paper›PMID 32587953›Full record

ArticleInternational journal of biomedical investigation

Identification of Novel Proteins Interacting with Proprotein Convertase Subtilisin/Kexin 9.

Quantil M Melendez, Catherine J Wooten, Sreevidhya T Krishnaji, Kevin Knagge, David Kirchner, Dayami Lopez

Open access · diamondAbstract read
In one paragraph

Article in International journal of biomedical investigation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Genome-Wide Association Study HighlightsArteriosclerosis, thrombosis, and vascular biology · 2021
    Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Quantil M MelendezDepartment of Pharmaceutical Sciences, Biomanufacturing Research Institute and Technology Enterprise (BRITE), College of Arts and Sciences, North Carolina Central University, Durham, USA.
Catherine J WootenDepartment of Pharmaceutical Sciences, Biomanufacturing Research Institute and Technology Enterprise (BRITE), College of Arts and Sciences, North Carolina Central University, Durham, USA.
Sreevidhya T KrishnajiIndian Institute of Science Education and Research Bhopal, Madhya Pradesh, India.
Kevin KnaggeDavid H Murdock Research Institute, Kannapolis, USA.
David KirchnerDavid H Murdock Research Institute, Kannapolis, USA.
Dayami LopezDepartment of Pharmaceutical Sciences, Biomanufacturing Research Institute and Technology Enterprise (BRITE), College of Arts and Sciences, North Carolina Central University, Durham, USA.
North Carolina Central University · US

Funding

Understanding Perceptions of HIV Risk, PrEP, and PrEP use among African American Women Attending an HBCUU54MD012392 · NIMHD · NORTH CAROLINA CENTRAL UNIVERSITY · PI Cherise Baldwin Harrington, DEEPAK KUMAR · 2017 to 2026
$38.1M
Effects of A1AT on PCSK9 expression and functionSC1GM131974 · NIGMS · NORTH CAROLINA CENTRAL UNIVERSITY · PI LOPEZ, DAYAMI · 2019 to 2022
$1.5M
NIGMS NIH HHS SC1 GM131974NIMHD NIH HHS U54 MD012392
6 · The paper itself

Abstract

High levels of cholesterol, especially as low-density lipoprotein (LDL), are a well-known risk factor for atherosclerotic-related diseases. The key atherogenic property of LDL is its ability to form atherosclerotic plaque. Proprotein convertase subtilisin/kexin-9 (PCSK9) is an indirect regulator of plasma LDL levels by controlling the number of LDL receptor molecules expressed at the plasma membrane, especially in the liver. Herein, we performed a combination of affinity chromatography, mass spectrometry analysis and identification, and gene expression studies to identify proteins that interact with PCSK9. Through these studies, we identified three proteins, alpha-1-antitrypsin (A1AT), alpha-1-microglobulin/bikunin precursor (AMBP), and apolipoprotein H (APOH) expressed by C3A cells that interact with PCSK9. The expression levels of A1AT and APOH increased in cells treated with MITO+ medium, a condition previously shown to affect the function of PCSK9, as compared to treating with Regular (control) medium. However, AMBP expression did not change in response to the treatments. Additional studies are required to determine which of these proteins can modulate the expression/function of PCSK9. The identification of endogenous modulators of PCSK9's function could lead to the development of novel diagnostic tests or treatment options for patients suffering hypercholesterolemia in combination with other chronic metabolic diseases.

Indexed as

A1ATAMBPAPOHEndogenous regulatorHypercholesterolemiaPCSK9Protein-protein interactions

Identifiers

PMID32587953
PMCPMC7316369
OpenAlexW3037177085

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.